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32 The Journal of Thoracic and Cardiobjectives: B-type natriuretic peptide, a cardiac hormone with diuretic, natriuretic,
nd vasoactive properties, is used in the diagnosis, risk stratification, and manage-
ent of adult cardiac patients. However, no study has yet determined the prognostic
alue of B-type natriuretic peptide after surgical intervention for congenital heart
isease. The objectives of this study were (1) to determine alterations in B-type
atriuretic peptide levels after repair of congenital heart disease with cardiopulmo-
ary bypass and (2) to investigate potential associations between B-type natriuretic
eptide levels and outcomes in this patient population.
ethods: Fifty-one infants and children undergoing repair of congenital heart
isease were studied. B-type natriuretic peptide levels were measured before and
fter surgical intervention, and the ability of the postoperative 12-hour B-type
atriuretic peptide level to predict postoperative outcomes was evaluated.
esults: B-type natriuretic peptide levels increased after separation from cardiopul-
onary bypass, with an 8-fold peak increase at 12 hours (P  .005). Postoperative
2-hour B-type natriuretic peptide levels were associated with the duration of
echanical ventilation and the presence of a low cardiac output state after surgical
ntervention. On multivariate analysis, the 12-hour B-type natriuretic peptide level
as an independent predictor of the duration of mechanical ventilation. In fact,
-type natriuretic peptide levels of greater than 540 pg/mL predicted mechanical
entilation beyond 48 hours, with a sensitivity of 88.9% and a specificity of 82.5%.
n addition, B-type natriuretic peptide levels of greater than 815 pg/mL predicted the
resence of a low cardiac output state within 48 hours after surgical intervention,
ith a sensitivity of 87.5% and a specificity of 90.2%.
onclusions: B-type natriuretic peptide determinations might be a useful tool for
linicians caring for infants and children after surgical intervention for congenital
eart disease.
espite numerous advances, surgical intervention for patients with congenital
heart disease continues to carry significant morbidity and mortality. Ac-
cordingly, considerable resources, including specialized intensive care, are
sed postoperatively, and yet up to 25% of infants and young children have
iminished cardiac output within the first 24 hours.1,2 Management during this
eriod is complicated by a dearth of validated physiologic markers to guide therapy,
esulting in a substantial reliance on subjective clinical assessments. Direct mea-
urements of hemodynamic indices, such as cardiac output, are often not possible in
hese patients because of altered blood flow (eg, intracardiac shunting), size limi-
ations that preclude invasive monitoring, or both, making the continued search for
uch reliable markers important.
vascular Surgery ● March 2006
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DB-type natriuretic peptide (BNP) is a 32-amino-acid
olypeptide hormone with diuretic, natriuretic, and vasoac-
ive properties that is secreted by the cardiac ventricles in
esponse to myocyte stretch.3 Determinations of BNP are
ncreasingly used in the diagnosis, risk stratification, and
anagement of adult cardiac patients.4-7 Much less data
xist on the role of BNP in pediatric patients with cardiac
isease, and no study has yet determined the prognostic
alue of BNP levels after surgical repair of structural con-
enital heart defects.8-13
The objectives of this study were thus (1) to determine
lterations in BNP levels over time after repair of congenital
eart defects with cardiopulmonary bypass (CPB) and (2) to
nvestigate potential associations between BNP levels and
utcomes in this patient population. We prospectively stud-
ed 51 infants and children undergoing complete repair of
tructural congenital heart defects with CPB. Systemic ar-
erial plasma BNP determinations were made before and 2,
2, and 24 hours after CPB. We then evaluated the ability of
he 12-hour BNP level to predict postoperative outcomes.
ethods
ubjects
his prospective cohort study was conducted at the Pediatric
ardiac Intensive Care Unit (PCICU) at the University of Califor-
ia, San Francisco. Patients with congenital heart defects under-
oing complete surgical repair with CPB were enrolled. Patients
ere excluded from the study if they required staged single-
entricle palliation or were unable to separate from CPB and
equired extracorporeal life support postoperatively.
The patients were followed up during their entire course in the
CICU. The perioperative anesthesia management, CPB strategy,
nd subsequent PCICU management followed standard institu-
ional practices. After surgical repair, all patients were admitted to
he PCICU intubated and mechanically ventilated. An on-service
eam that was blinded to the BNP values made all decisions
egarding patient management.
Written informed consent was obtained from the patients’
arents or guardians before enrollment of the patients into the
tudy. The institutional review board at the University of Califor-
ia, San Francisco, reviewed and approved this study.
ata Collection
lood samples were obtained from an arterial catheter preopera-
ively and at 2, 12, and 24 hours after CPB. The samples were
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
CPB  cardiopulmonary bypass
PCICU Pediatric Cardiac Intensive Care Unit
SvO2 mixed venous oxyhemoglobin saturationmmediately placed on ice in prechilled ethylenediamine tetraace- m
The Journal of Thoracicic acid tubes and centrifuged at 3000 rpm for 15 minutes at 4°C.
eparated plasma was stored at20°C. Within 4 days of obtaining
he sample, the plasma was thawed to room temperature, and BNP
evels were measured with a commercially available fluorescence
mmunoassay (Triage Meter Plus, Biosite Diagnostic). The mea-
urable range of BNP on this device is between 5 and 5000 pg/mL.
he average 95% confidence limit of the analytic sensitivity for the
riage BNP test is less than 5 pg/mL.
Clinical and laboratory data were prospectively collected at
ach sampling point and once daily thereafter by an observer
linded to the BNP data. The clinical data collected included
emographics, CPB time, crossclamp time, duration of mechanical
entilation, inotrope dosage, mean systemic arterial pressure, cen-
ral venous pressure, and fluid balance. Laboratory data included
ase deficit, venous blood gases, and serum lactate levels.
reoperative Classification of Cardiac Defect
ardiac lesions were classified as having decreased, normal, or
ncreased pulmonary blood flow to investigate associations be-
ween preoperative BNP levels and preoperative cardiac physiol-
gy. Lesions classified as having decreased pulmonary blood flow
ncluded pulmonary atresia, tetralogy of Fallot, and pulmonary
tenosis. Lesions classified as having increased pulmonary blood
ow included atrial septal defect, ventricular septal defect, atrio-
entricular septal defect, truncus arteriosus, transposition of the
reat arteries, and totally anomalous pulmonary venous return.
alculations
notrope use was quantified by a score adapted from Wernovsky
nd colleagues.2 The score was calculated by obtaining the total
mount of inotropic support the patients received at each sampling
oint and then entering the data into the following equation:
opamine Dobutamine ([Epinephrine
 Norepinephrine]  100)Milrinone  20).
Units of inotrope dosage used in this equation were in micro-
rams per kilogram per minute.
The definition of a low cardiac output state was identical to
riteria published by Hoffman and coworkers.1 Low cardiac output
tate was defined by a combination of changes in clinical signs and
iochemical indicators and the administration of interventions
imed at augmenting cardiac output, including increased pharma-
ologic support relative to the baseline and mechanical pacing.
linical signs included tachycardia, oliguria, poor perfusion, or
ardiac arrest occurring with or without a widened arterial–mixed
enous oxyhemoglobin saturation (SvO2) difference or metabolic
cidosis.
nalysis of the Data
nalysis of continuous variables within categories was made with
tests and analysis of variance or the nonparametric Mann-
hitney and Kruskal-Wallis tests, as appropriate. Because of their
onnormal distribution, BNP levels were log transformed. A linear
egression model was used to assess the association between the
og-transformed 12-hour BNP levels and the primary predictor (ie,
he duration of mechanical ventilation). A logistic regression
odel was used to assess the association between 12-hour BNP
and Cardiovascular Surgery ● Volume 131, Number 3 633
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Devels and the presence of a low cardiac output state. Next, the
uration of mechanical ventilation was dichotomized to being
qual to or less than 48 hours or greater than 48 hours. Receiver
perating characteristics curves were used to assess the various
utoff values of BNP to predict (1) the need for mechanical
entilation beyond 48 hours and (2) the development of a low
ardiac output state within 48 hours of surgical intervention.
esults
ifty-one patients were initially enrolled in this study. How-
ver, 2 patients could not be separated from CPB, and they
equired extracorporeal life support and were therefore ex-
luded from the study. Of the 49 patients included in the
tudy, 27 were male and 22 were female. Their ages ranged
rom 1 day to 15 years of age. The types of cardiac defects,
emographics, and other baseline data are shown in Table 1.
here was no mortality among the enrolled patients during
he study period.
Preoperative BNP levels ranged from 5 to 1140 pg/mL.
here was an inverse relationship between preoperative
NP levels and weight (rhos  0.51, P  .002) and age
rhos  0.48, P  .0006). There was no difference in the
evels of preoperative BNP with the sex of the patient (P 
19). Although there was a trend toward increasing BNP
evels across categories of increasing pulmonary blood
ow, this difference was not statistically significant. Twenty
tudy patients were treated for congestive heart failure
CHF) before surgical intervention. There was a statistically
ABLE 1. Demographics and patient characteristics
emographics
Age (d), median (range) 331 (1-5655)
Weight (kg), median (range) 9.6 (2.5-76)
Male sex 55%
Female sex 45%
ype of lesion n
ASD 9
AV canal 4
Aortic insufficiency 2
Aortic stenosis 3
Mitral insufficiency 1
Mitral stenosis 1
Pulmonary atresia 1
Pulmonary insufficiency 2
TAPVR 1
Tetralogy of Fallot 7
Transposition of the great arteries 5
Truncus arteriosis 4
VSD 9
PB time (min), median (range) 81 (25-157)
rossclamp time (min), median (range) 44 (0-87)
SD, Atrial septal defect; AV, atrioventricular; TAPVR, total anomalous
ulmonary venous return; VSD, ventricular septal defect; CPB, cardiopul-
onary bypass.ignificant difference in preoperative BNP levels between n
34 The Journal of Thoracic and Cardiovascular Surgery ● Marcatients treated for CHF and those not treated for CHF
median values, 82.6 vs 14.7 pg/mL; P  .006).
On serial follow-up, BNP levels increased over time
fter discontinuation of CPB, reaching a peak at 12 hours
 P  .001, Table 2). Postoperatively, BNP levels reached
peak at 12 hours in 62% of the patients. The change in
NP over time is depicted in Figure 1. The 12-hour BNP
evel had a significant correlation with the duration of
echanical ventilation (rho  0.66, P  .0001), bypass
ime (rho  0.51, P  .0002), and aortic crossclamp time
rho  0.28, P  .046). The relationship between the
og-transformed hours of mechanical ventilation and BNP lev-
ls was linear (Figure 2). O n univariate linear regression
nalysis, the 12-hour BNP level was a significant predictor
f the duration of mechanical ventilation (r2  0.32, coef-
cient  13.5, P  .0001). Other variables that were
redictors of the duration of mechanical ventilation on
nivariate analysis included preoperative BNP level, bypass
ime, 12-hour mean systemic arterial pressure, and age.
ariables that were not associated with the duration of
echanical ventilation included 12-hour inotrope score, 12-
our lactate level, 12-hour central venous pressure, and
igure 1. Box plots showing the change in B-type natriuretic
eptide (BNP) before and after cardiopulmonary bypass. Boxes
how the interquartile range, and I-bars represent the highest and
owest values. BNP levels are log transformed because of non-
ABLE 2. BNP levels before and after CPB
ime points N
Median
(pg/mL) Interquartile range P value
efore CPB 48 38.3 13.3-96.8 .0001
h after CPB 47 58.3 22.2-363.0
2 h after CPB 49 301.0 166.0-642.0
4 h after CPB 48 261.0 150.0-413.0
NP, B-type natriuretic peptide; CPB, cardiopulmonary bypass.ormal distribution.
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D4-hour fluid balance. On multivariate linear regression
nalysis, by a backward stepwise elimination model, the
2-hour BNP level was an independent predictor of the
uration of mechanical ventilation.
Twelve-hour BNP levels were higher in the 15 patients
equiring mechanical ventilation beyond 48 hours (P 
0002, Figure 3). A receiver operating curve, which was
sed to evaluate the various cutoff levels of 12-hour BNP to
igure 2. Scatter plot showing the relationship between 12-hour
-type natriuretic peptide (BNP) levels and the duration of me-
hanical ventilation. Because of nonnormal distribution, the data
ave been log transformed.
igure 3. Box plots showing the relationship of 12-hour B-type
atriuretic peptide (BNP) to the need for mechanical ventila-
ion beyond 48 hours. Boxes show the interquartile range, and
-bars represent the highest and lowest values. Twelve-hour
NP levels are log transformed because of nonnormal distri-aution.
The Journal of Thoracicredict the need for mechanical ventilation beyond 48 hours
fter surgical intervention, had an area under the curve of
7.7% (95% confidence interval, 76.8%-96.8%; Figure 4).
12-hour BNP cutoff value of 540 pg/mL or more had a
ensitivity of 88.9%, a specificity of 82.5%, a positive predic-
ive value of 54%, and a negative predictive value of 97% for
redicting the need for mechanical ventilation beyond 48
ours. No patient in this study required reintubation.
Twelve-hour BNP levels were also higher in the 11
atients who had a low cardiac output state within the first
8 hours after CPB (P  .0001, Figure 5). On logistic
egression, development of a low cardiac output state within
he first 48 hours had an odds ratio of 1.28 for every 100-pg
ncrease in the 12-hour BNP level. A receiver operating
urve, which was used to evaluate the various cutoff levels
f 12-hour BNP to predict the development of a low cardiac
utput state within 48 hours after CPB, had an area under
he curve of 91.4% (95% confidence interval, 80%-100%;
igure 6). A 12-hour BNP cutoff level of 815 pg/mL or
ore had a sensitivity of 87.5%, a specificity of 90.2%, a
ositive predictive value of 64%, and a negative predictive
alue of 97% for predicting the presence of a low cardiac
utput state within the first 48 hours.
iscussion
he principal findings of this study are as follows: (1) BNP
evels increase in pediatric patients with congenital heart
efects after surgical repair with CPB and (2) BNP levels 12
ours after CPB are predictive of a requirement for mechan-
cal ventilation beyond 48 hours and the presence of a low
ardiac output state within the first 48 hours postopera-
ively. This is the largest study to date evaluating perioper-
igure 4. Receiver operating characteristic curve of the various
utoff levels of 12-hour B-type natriuretic peptide in predicting
he need for mechanical ventilation beyond 48 hours. A cutoff
alue of 540 pg/mL has a sensitivity of 88.9% and a specificity of
2.5%.tive BNP levels in infants and children undergoing com-
and Cardiovascular Surgery ● Volume 131, Number 3 635
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Dlete repair of congenital heart defects. Moreover, to our
nowledge, this is the first study to demonstrate the prog-
ostic utility of BNP levels in this population, suggesting an
mportant role for their use in postoperative management.
BNP is a member of a structurally related group of peptide
ormones, termed natriuretic peptides, that also includes atrial
atriuretic peptide and C-type natriuretic peptide. BNP is pro-
uced predominantly in the cardiac ventricles. The primary
ctions of BNP are vascular smooth muscle relaxation,
iuresis, and natriuresis.3,14 Of the natriuretic peptides, BNP
as emerged as the most useful marker for the severity of
dult cardiac disease.4,5,15 We hypothesized that BNP
ould be a physiologically relevant marker of cardiac dys-
unction in infants and children after surgical intervention
or congenital heart disease.
Three studies have previously reported on changes in
NP after CPB in a pediatric population.9,13,16 Most re-
ently, Sun and colleagues13 measured BNP levels before
nd after surgical intervention in 27 patients undergoing
iventricular repair and 27 patients undergoing univentricu-
ar repair of congenital heart defects. Plasma BNP levels
ncreased after bypass in patients with biventricular defects
ut not in patients with univentricular defects, a group of
atients not included in our study. Ationu and associates16
easured perioperative BNP levels in 9 children undergo-
ng repair of congenital heart defects. Contrary to our find-
ngs, BNP levels decreased at 12 hours after surgical inter-
ention, which might relate to the inclusion of 4 patients
ho underwent total cavopulmonary connection.16 Finally,
igure 5. Box plots showing the relationship of 12-hour B-type
atriuretic peptide (BNP) levels to the development of a low
ardiac output within 48 hours after cardiopulmonary bypass.
oxes show the interquartile range, and I-bars represent the
ighest and lowest values. Twelve-hour BNP levels are log
ransformed because of nonnormal distribution.ostello and coworkers9 examined BNP levels before and i
36 The Journal of Thoracic and Cardiovascular Surgery ● Marcfter cardiac surgery with CPB in 5 infants with CHF
aused by left-to-right intracardiac shunts. Consistent with
ur data, BNP levels increased from preoperative levels at
he first postoperative day. These studies are limited by their
ample size and do not address correlations between BNP
nd postoperative clinical outcomes.
These issues have been better explored in the adult
opulation. A number of investigators have described a
onsistent increase in BNP levels after cardiac surgery with
PB.17-19 Furthermore, BNP levels have been associated
ith the presence and severity of ventricular dysfunction
fter surgical intervention.20 Finally, BNP levels have been
ssociated with the extent of cardiac support required post-
peratively, the duration of postoperative intensive care,
nd the incidence of cardiac events up to 2 years after
urgical intervention.18-20 Our study is in keeping with these
ndings but is unique in the demonstrated association be-
ween postoperative BNP levels and the duration of me-
hanical ventilation and in the evaluation of pediatric
atients.
To our knowledge, this is the first report that describes an
ssociation between BNP levels and the duration of me-
hanical ventilation after cardiac surgery. The duration of
echanical ventilation is commonly interpreted as an im-
ortant marker of disease severity. Indeed, at our institution,
ost pediatric patients do not require mechanical ventila-
ion beyond the first 24 to 36 hours after cardiac surgery.
herefore, we believed that dichotomizing the duration of
echanical ventilation to less than or greater than 48 hours
ould provide a clinically relevant outcome measure. In
act, there was significant overlap between patients requir-
Figure 6. Receiver operating characteristic curve of the various
cutoff levels of 12-hour B-type natriuretic peptide in predicting
the development of a low cardiac output state within 48 hours
after surgical intervention. A cutoff value of 815 pg/mL has a
sensitivity of 87.5% and a specificity of 90.2%.ng mechanical ventilation beyond 48 hours and those who
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Dad a low cardiac output state within 48 hours postopera-
ively. Validated criteria for extubation do not exist for
nfants and children after repair of congenital heart disease.
herefore, the attending physician made decisions regard-
ng extubation on an individual basis. These physicians
ere blinded to the BNP values, and decisions regarding the
iming of extubation conformed to the general approach of
he cardiac intensive care team, which includes extubating
ithin the first 24 hours when possible.
We report that BNP levels 12 hours after separation from
PB predict the development of a low cardiac output state
ithin the first 48 hours postoperatively. Eleven (22%)
atients had a low cardiac output state within this period.
his incidence is similar to that reported by several other
nvestigators who determined cardiac output in pediatric
atients after surgical intervention for congenital heart dis-
ase.1,2 Interestingly, BNP levels peaked at 12 hours after
PB, which correlates with the onset of a low cardiac output
tate in these studies as well.1,2 We did not use direct
easurements of cardiac output (eg, dye dilution) in our
efinition of a low cardiac output state but rather used a
omposite definition that incorporates clinical signs, bio-
hemical data, and the use of inotropic agents, vasoactive
gents, or both, or other interventions (eg, pacing) directed
t augmenting cardiac output. Although direct measures of
ardiac output would have been valuable, they were not
onsistently available in our population. Importantly, phy-
icians blinded to the BNP data made all therapeutic deci-
ions, including those that influenced the definition of a low
ardiac output state. Furthermore, the incidence of a low
ardiac output state in our study was similar to that reported
n studies that did directly measure cardiac output.2,21
Although the peak BNP level occurred 12 hours after
ypass and most strongly predicted the need for prolonged
echanical ventilation, it is noteworthy that 6 of the 11
atients who had low cardiac output did so within the first
2 hours. Therefore, these patients had low cardiac output
ither before or at the time of the 12-hour BNP sampling,
reventing the prognostic utility of this level. However,
oth the preoperative BNP level (odds ratio, 2.1 per 100-pg
ncrease in BNP; P  .012) and the 2-hour BNP level (odds
atio, 1.2 per 100-pg increase in BNP; P  .013) were also
redictive of the development of low cardiac output. There-
ore, these earlier time points might also have clinical utility
n this patient population.
We found that preoperative BNP levels were higher in
atients undergoing medical treatment for CHF. This is
onsistent with a number of studies that have established an
ssociation between BNP levels and the severity of ventric-
lar dysfunction in patients with congenital heart de-
ects.22-26 Furthermore, we found an inverse relationship
etween preoperative BNP levels and patient age and
eight. Developmental studies indicate that BNP levels are l
The Journal of Thoracicighest at birth but decrease by the first week of life and by
 weeks of age are generally lower than adult levels.27
espite higher BNP levels in small infants, who might be
xpected to require a prolonged duration of mechanical
entilation, BNP levels were independently predictive of
he duration of mechanical ventilation on multivariate re-
ression analysis.
Our data indicate that 12-hour postoperative BNP levels
ight be useful in the management of patients with con-
enital heart defects. Because clinical assessments have
imitations, biochemical tests that might help guide therapy
n the postoperative period are important. A number of
tudies have documented a significant correlation between
erum lactate levels and various outcome measures.28,29
ncreased serum lactate levels reflect inadequate tissue ox-
gen delivery with resultant anaerobic metabolism and thus
onfirm an inadequate cardiac output, as opposed to herald-
ng one. BNP release is stimulated by increased ventricular
olume or pressure, and thus levels could potentially in-
rease in advance of a decrease in tissue oxygen delivery. SvO2
s increasingly used as an indirect measure of cardiac output in
ediatric patients after cardiac surgery.30 SvO2changes rapidly
ith changes in cardiac output and thus enables the clinician
o titrate therapy in advance of tissue hypoxia. Unfortu-
ately, accurate measures of SvO2 are often not possible
ecause of vascular access limitations, intracardiac shunt-
ng, or both, which can diminish the reliability of the mea-
ured values.
Several limitations of the present study are noteworthy.
irst, we excluded patients undergoing palliation of single-
entricle cardiac defects. Although we believed that our
nitial analysis would be best focused on a homogeneous
opulation (ie, infants and children undergoing complete
epair of congenital heart defects), the exclusion of this
opulation prevents us from determining the utility of BNP
evels in the management of our most tenuous patients.
uture studies are planned to include these patients. Indeed,
he stimuli for BNP release (ie, ventricular volume and
ressure) might make it a particularly useful clinical marker
or patients with single-ventricle disease, especially in re-
ard to the timing of a cavopulmonary connection. In ad-
ition, this initial investigation contained a heterogeneous
opulation of study patients with varying risks of perioper-
tive morbidity and mortality. Future studies on more ho-
ogenous populations are warranted. Last, patients requir-
ng extracorporeal life support were excluded from our
nalysis. BNP levels were measured at time points after
PB that were determined a priori. Thus, we could not
nclude patients who were unable to be separated from CPB
ostoperatively.
Myocardial dysfunction after surgical intervention for
ongenital cardiac disease is a common and complex prob-
em. Alterations in levels of BNP, a cardiac hormone, reflect
and Cardiovascular Surgery ● Volume 131, Number 3 637
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Dberrant myocardial dynamics in a manner not captured by
ther physiologic markers. Indeed, our data indicate that
NP might be a better predictor of prolonged ventilation
han other more commonly used measures, such as bypass
ime, mean systemic arterial pressure, lactate levels, and
uid balance. Further studies are warranted to investigate
he utility of BNP as a therapeutic guide in this population.
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